A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Rai SC, Kim S, Burden A, Alho AC, Lacerda JF, Alyea EP, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J, Koreth J.
Whangbo JS, et al. Among authors: soiffer rj.
Blood Adv. 2022 Nov 8;6(21):5786-5796. doi: 10.1182/bloodadvances.2021006625.
Blood Adv. 2022.
PMID: 35475885
Free PMC article.
Clinical Trial.